Loading…
Loading…
can you help us sort of frame the Abbott Laboratories portfolio in EP maybe looking back six months, where we are today
could you maybe talk a little bit more on some of the underlying drivers of the business and how you think about an overall acceleration in the Diagnostics business going forward
help us think through the headwinds you're seeing this year, the extent to which those are transient versus more permanent changes
think about where you're positioned and how you accelerate this business back toward end market growth
you could go into a little bit more detail on the Structural Heart business
how you saw these dynamics play out through the back half of 2025
is there anything left either from a technology standpoint, maybe a vessel sealer that you think would be necessary to really unlock the opportunity?
how you're seeing that unfold and where force feedback fits into that trajectory
You've had a number of SP clearances over the past six months or so. Maybe just help us contextualize performance
it looks like I&A outgrew procedure volumes this quarter, whether that's having a positive impact even in its early launch
Can you maybe give us an update on your latest thinking on the capital side and how you're approaching those conversations
maybe, Gary, you could expand a little bit on the comment made earlier about Intuitive being potentially part of the solution and not part of the problem
can you help us think through which parts of sort of the surgical ecosystem you've captured today? And maybe give us some sense of where that might be going
Is this something that you're observing today as you talk to customers outside the US or even in the US? Or are you just calling out a theoretical impact
I wanted to come back to just the overall MedTech strategy. And I appreciate that you exited the year over the 7% number